Merck & Co has announced plans to acquire a private US company that has developed a new insulin formulation for the treatment of diabetes mellitus. The transaction is valued at in excess of $500 million assuming milestones are met. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
